No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial

EuroIntervention. 2026 Apr 20;22(8):e455-e462. doi: 10.4244/EIJ-D-25-01307.ABSTRACTThe current standard regimen for antithrombotic therapy after percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) recommends long-term use of antiplatelet agents.

T Toshiaki Otsuka